Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carboplatin + etoposide + tislelizumab
- Development stage
- Unknown
- Lead developer
- BeiGene
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Carboplatin + etoposide + tislelizumab is a combination regimen used primarily for the treatment of extensive-stage small cell lung cancer (ES-SCLC). Carboplatin and etoposide are chemotherapeutic agents that work by damaging DNA and inhibiting cell division, leading to cancer cell death. Tislelizumab is a monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor on immune cells, blocking its interaction with PD-L1 and PD-L2 ligands. This blockade releases the inhibition on T-cell activity, enhancing the immune system's ability to recognize and attack tumor cells. The combination has demonstrated improved overall survival and progression-free survival compared to chemotherapy alone in phase 3 clinical trials for ES-SCLC[1][3][4].
- Brand names
- Tevimbra
- Other names
- TEC regimen
02
Targets
TOP2A (DNA topoisomerase II)DNAPDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on carboplatin + etoposide + tislelizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carboplatin + etoposide + tislelizumab.